Kerendia (finerenone)

Brand Options

arrow pointer

Brand Name : Kerendia

Marketing Authorization Holder : Bayer

Prescription Required

 
 
No Generic Medicine available for this medicine.

Product Details

Kerendia

Save over 67% buying Karendia.

Manufacturer of all European product (including that shipped from India): Bayer AG Kaiser-Wilhelm-Allee 51368 Leverkusen Germany

Information about Kerendia (Finerenone)

Kerendia (finerenone) is a selective mineralocorticoid receptor antagonist (MRA) used primarily for the treatment of chronic kidney disease (CKD) associated with type 2 diabetes. It works by blocking the effects of aldosterone, which can contribute to kidney damage.

Product Highlights

The treatment of chronic kidney disease in adults with type 2 diabetes to slow the progression of kidney disease and reduce the risk of cardiovascular events.

Key Ingredient

  • Finerenone

Key Benefits

  • Helps to slow the progression of CKD in patients with type 2 diabetes.
  • Reduces the risk of cardiovascular events, such as heart attack or stroke, in at-risk patients.
  • The selective action may lead to a lower incidence of hyperkalemia (elevated potassium levels) compared to traditional MRAs.

Direction of Use

  • The recommended starting dose is typically 10 mg once daily, which may be adjusted based on patient response and tolerance.
  • Can be taken with or without food; swallow tablets whole.
  • Regular monitoring of kidney function and potassium levels is essential during treatment.

Recommended Starting Dosage

eGFR (mL/min/1.73m2 )Starting Dose
≥ 6020 mg once daily
≥ 25 to < 6010 mg once daily
< 25Not Recommended

Safety Concerns

  • Risk of elevated potassium levels; monitoring is required.
  • May affect renal function; adjustments may be necessary based on lab results.
  • Potential for low blood pressure, especially in patients on multiple antihypertensive medications.

Avoid Kerendia (Finerenone) If

  • History of allergy to finerenone or any of its ingredients.
  • Avoid use in patients with severe renal impairment (eGFR < 25 mL/min).
  • Should not be used in patients with significant hyperkalemia (potassium > 5.5 mEq/L) at baseline.


Image Image Image Image